REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures

Market cap (intra-day) 561.57B
Enterprise value 359.45B
Trailing P/E 30.11
Forward P/E 118.93
PEG ratio (5-yr expected) 12.62
Price/sales (ttm)7.40
Price/book (mrq)5.49
Enterprise value/revenue 37.15
Enterprise value/EBITDA 622.18

Trading information

Stock price history

Beta (5Y monthly) 0.53
52-week change 3102.88%
S&P500 52-week change 38.60%
52-week high 3615.36
52-week low 3271.37
50-day moving average 3554.80
200-day moving average 3442.74

Share statistics

Avg vol (3-month) 31.6M
Avg vol (10-day) 36.05M
Shares outstanding 5100.87M
Float 83.68M
% held by insiders 123.82%
% held by institutions 168.35%
Shares short (14 May 2020) 41.78M
Short ratio (14 May 2020) 41.66
Short % of float (14 May 2020) 42.15%
Short % of shares outstanding (14 May 2020) 41.58%
Shares short (prior month 14 Apr 2020) 42.01M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)30 Mar 2020


Profit margin 27.40%
Operating margin (ttm)29.63%

Management effectiveness

Return on assets (ttm)10.77%
Return on equity (ttm)21.13%

Income statement

Revenue (ttm)8.32B
Revenue per share (ttm)76.03
Quarterly revenue growth (yoy)33.20%
Gross profit (ttm)4.04B
Net income avi to common (ttm)2.28B
Diluted EPS (ttm)19.91
Quarterly earnings growth (yoy)35.50%

Balance sheet

Total cash (mrq)4B
Total cash per share (mrq)35.95
Total debt (mrq)715.2M
Total debt/equity (mrq)5.89
Current ratio (mrq)4.21
Book value per share (mrq)109.28

Cash flow statement

Operating cash flow (ttm)2.23B
Levered free cash flow (ttm)1.28B